Exploiting UChicago research, Reflexion is eyeing an expansion in Asia after receiving $40m in additional series D funding to bring the round to $150m.

Reflexion, a US-based oncology therapy technology developer partly based on University of Chicago research, secured $40m on Tuesday from healthcare-focused investment firm Ally Bridge Group to expand its series D round to $150m. The company said it raised $110m of series D funding across 2020, including $100m from investors including Pfizer Ventures and Johnson &…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.